A major clinical trial of retatrutide, a new obesity drug, found it did not considerably reduce the risk of death, heart attack, or stroke compared to a placebo on secondary measures.
A new weight-loss drug being watched closely by researchers has failed to show a clear benefit for the heart in a key part of its clinical trial, according to a report posted by medical news outlet StatNews. The drug, retatrutide — a type of injectable medicine that targets multiple gut hormones to reduce appetite and body weight — did not produce a statistically significant reduction in major cardiovascular events (serious heart and blood vessel problems) when researchers examined those outcomes as secondary, rather than primary, trial goals.
The finding matters because reducing heart risk is one of the most closely watched goals in obesity medicine. Rival drugs in the same class, known as GLP-1 receptor agonists, have already shown cardiovascular benefits in large trials — so the absence of a similar signal in retatrutide’s secondary data will draw scrutiny from cardiologists and regulators alike.
Secondary endpoints are pre-specified measures that a trial is not primarily designed to prove. A result that falls short of significance there doesn’t mean the drug caused harm — but it does mean the evidence of heart protection isn’t yet established.
No Kent-specific data, local NHS guidance, or regional service changes are connected to this trial at this stage. The drug is not currently available on the NHS.
Anyone with concerns about their heart health, weight, or eligibility for existing weight-management services should speak to their GP or call NHS 111.
Key information
- NHS 111 — call 111 for non-emergency health queries, 24 hours a day
- 999 — call in an emergency, including chest pain or suspected heart attack
- Your GP — the right first contact for questions about weight management or cardiovascular risk
Source: @statnews